TIDMVLG

RNS Number : 5949I

Venture Life Group PLC

14 December 2020

14 December 2020

Venture Life Group plc

("Venture Life" or the "Company")

Exercise of Share Options & Voting Rights

Venture Life (AIM: VLG), a leading developer, manufacturer and distributer of consumer self-care products, announces that is has issued 21,000 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") in accordance with an exercise of employee share options.

Application will be made to the London Stock Exchange for the 21,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 21 December 2020.

Following Admission, the total number of Ordinary Shares in issue will be 125,831,530 and the total number of voting rights will therefore be 125,831,530. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

   Venture Life Group PLC     +44 (0) 1344 578004 

Jerry Randall, Chief Executive Officer

Andrew Waters, Chief Financial Officer

   Cenkos Securities plc (Nomad and Joint Broker)     +44 (0) 20 7397 8900 

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

N+1 Singer (Joint Broker)

   Shaun Dobson / Carlo Spingardi (Corporate Finance)      +44 (0) 20 7496 3000 

Jonathan Dighe (Sales)

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFFMFLLESSESE

(END) Dow Jones Newswires

December 14, 2020 09:07 ET (14:07 GMT)